{
    "clinical_study": {
        "@rank": "112711", 
        "acronym": "ArenA", 
        "arm_group": {
            "arm_group_label": "Bolus ONS intake", 
            "arm_group_type": "Other", 
            "description": "Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS =  oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number."
        }, 
        "brief_summary": {
            "textblock": "In this study healthy older adults are requested to consume 4 different high-protein\n      nutritional supplements. Each subject will visit the site 4 times and at every visit they\n      will consume 1 of the 4 products after which a series of blood samples will be taken. The\n      blood samples will be analyzed for amino acid bioavailability in the blood up to 4 hours\n      after consumption."
        }, 
        "brief_title": "Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Sarcopenia", 
        "condition_browse": {
            "mesh_term": "Sarcopenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 65 years or older\n\n          -  BMI between 21 and 30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that may interfere with the definition 'healthy elderly' according to\n             the investigator's judgement.\n\n          -  Any (history of) gastrointestinal disease that interferes with GI function (e.g.\n             inflammatory bowel disease, gastroparesis, gastrectomy).\n\n          -  Known allergy to milk and milk products.\n\n          -  Known galactosaemia.\n\n          -  Current or recent (within past three months) smoking.\n\n          -  Known or suspected Diabetes Mellitus.\n\n          -  Current infection or fever in the last 7 days at the discretion of the physician.\n\n          -  Use of antibiotics within 3 weeks of study entry.\n\n          -  Current use of corticosteroids or hormones.\n\n          -  Current use of antacids or any medication influencing gastric acid production.\n\n          -  Requirement for any nutritional support.\n\n          -  Unplanned body weight loss > 5% in the past 3-6 months.\n\n          -  Adherence to any specific diet (e.g. weight loss, vegetarian).\n\n          -  Use of protein containing or amino acid containing nutritional supplements within one\n             week of study entry.\n\n          -  Alcohol or drug abuse.\n\n          -  Investigator's uncertainty about the willingness or ability of the subject to comply\n             with the protocol requirements.\n\n          -  Participation in any other study with investigational products concomitantly or\n             within 4 weeks of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013466", 
            "org_study_id": "Sip.1.C/B"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bolus ONS intake", 
                "description": "High-whey protein, leucine-rich, low-caloric ONS in powder format", 
                "intervention_name": "Bolus ONS A", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Bolus ONS intake", 
                "description": "High casein-protein, low-caloric control product (isocaloric to product A)", 
                "intervention_name": "Bolus ONS B", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Bolus ONS intake", 
                "description": "High casein-protein, high-caloric control product.", 
                "intervention_name": "Bolus ONS C", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Bolus ONS intake", 
                "description": "high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)", 
                "intervention_name": "Bolus ONS D", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bioavailability", 
            "Amino Acids", 
            "Elderly", 
            "Supplement"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands"
                }, 
                "name": "Ampha"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Amino Acid Bioavailability in Healthy Elderly After Bolus Intake of a High Whey-protein, Leucine-rich, Low-caloric Oral Nutritional Supplement", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands:  Independent Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome parameter in this study is the Maximum serum leucine concentration (Leumax) [micromol/L].", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013466"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum leucine incremental area under the curve (iAUC) [micromol/L*min].", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Time to reach half the serum leucine iAUC (t\u00bd) [minutes].", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Maximum serum essential amino acid concentration (EAAmax) [micromol/L]", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Maximum serum amino acid concentration (AAmax) [mmol/L]", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Maximum serum insulin concentration [micromol/L].", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Serum insulin iAUC [micromol/L*min]", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Maximum serum glucose concentration [mmol/L]", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Serum glucose iAUC [mmol/L*min]", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours after each bolus intake (4 visits, 7-10 days between 2 consecutive visits)"
            }, 
            {
                "measure": "Adverse events and (Gastro-Intestinal) tolerance questionnaire.", 
                "safety_issue": "Yes", 
                "time_frame": "During the study and until one week after completion of the study"
            }
        ], 
        "source": "Nutricia Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nutricia Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}